Oxoid targets emerging infectious agent:
This article was originally published in Clinica
Microbiology diagnostics firm Oxoid has launched a test for nanobacteria, an emerging infectious agent that may be involved with calcification diseases, such as polycystic kidney disease, and may even play a role in some cancers and autoimmune diseases. The Nanocapture ELISA kit detects the nanobacterial antigen in blood or plasma. It is intended for use in research settings and is the only commercially available kit for the agent, the Basingstoke, UK firm claims.